

2. (Amended) The composition of Claim 1, wherein the ability to bind $\alpha_v\beta_3$ integrin is RGD-independent.

3. (Amended) The composition of Claim 2, further comprising the inability to inhibit tumor cell proliferation.

4. (Amended) An isolated fragment of $\alpha 3(\text{IV})$ NC1 domain, having the amino acid sequence of amino acid residue 54 to amino acid 124 of SEQ ID NO:10.

Please add new claims 8-9 as follows:

8. (New) An isolated fragment of $\alpha 3(\text{IV})$ NC1 domain, having the amino acid sequence of amino acid residue 1 to amino acid residue 132 of SEQ ID NO:10.

9. (New) An isolated fragment of $\alpha 3(\text{IV})$ NC1 domain, having the amino acid sequence of amino acid residue 181 to amino acid residue 244 of SEQ ID NO:10.

REMARKS

Claims 1-4 are currently pending in the application. Claims 5-7 are canceled. Claims 1-4 are amended, the amendments finding support throughout the specification as filed, such as at pages 61, lines 20-24; page 65, lines 1-3; page 66, line 6-15; etc. New claims 8-9 are added, and find support in the specification as filed, e.g., at page 34, line 29 to page 35, line 1, and at page 35, lines 1-3, 9 and 11, etc. No new matter is added.

Title of the Invention

The Examiner has stated on page 2 of the Office Action that the title of the invention should convey to those skilled in the art the subject matter of the instant invention, and that the title should therefore give reference to fragments of the $\alpha 3(\text{IV})$ NC1 domain of collagen.